• Hasten

  Led · Equity · Apr 2023

  Hasten is an innovation-driven pharmaceutical company building a commercial platform and a late-stage development pipeline of innovative assets. The company has pursued inorganic growth, including acquiring Chinese‑mainland exclusive rights for five cardiovascular and metabolism drugs from Takeda in March 2022. Management says proceeds from fundraising will be used to fund future acquisitions and business development of pipeline assets and to create a broader health management ecosystem in China. Hasten reported 47% growth in sales from Q2 to Q4 in 2022, which CBC cited as evidence of operational and growth momentum. The company is backed by CBC, Hefei Industry Investment Group, and Feidong County of Hefei City, and management aims to become a leading healthcare company serving chronic, age‑related, acute and severe disease patients.

• Sironax

  Participated · Series B · Aug 2022

  Sironax is a Beijing-based clinical-stage biotechnology company dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Its pipeline comprises multiple programs focused on key mechanisms including regulated cell death, neuroprotective pathways and neuroinflammation, with lead efforts around RIPK1 inhibitors. The company is conducting early clinical studies with SIR0365 and SIR2446 while advancing additional preclinical research. Sironax plans to use recent financing to support ongoing clinical development of its RIPK1 portfolio and to expand its R&D footprint and pipeline of potential best- and first-in-class candidates. The company closed a $200M Series B led by Gaorong Capital and Yunfeng Capital, with participation from a broad group of existing and new investors. Led by CEO Aaron Ren and founded in 2017, Sironax is positioning to progress its clinical programs targeting age-related degeneration.

• ENSEM Therapeutics

  Participated · Series A · Apr 2022

  Ensem Therapeutics is a drug discovery and development company that leverages its Kinetic Ensemble platform to develop innovative small molecule precision medicines for oncology. The Kinetic Ensemble platform integrates computational and AI deep learning methodologies with advanced experimental techniques to identify non-obvious binding pockets and accelerate structure-based drug design. The company focuses on high-value and difficult-to-drug targets and may expand into genetic disorders and other disease areas. Ensem is led by CEO Sean Cao and is based in Boston, MA. In August 2022 the company raised $67M in a Series A financing, which it intends to use to further advance the Kinetic Ensemble platform and accelerate its R&D pipeline. Participants in the round included Pavilion Capital, Cenova Capital, Mitsui & Co. Global Investment and CBC Group.

• NiKang Therapeutics

  Participated · Series C · May 2021

  NiKang Therapeutics is a clinical-stage biotech focused on discovering and developing innovative small-molecule oncology medicines. The company’s discovery approach is informed by target structure biology and capitalizes on structure-based drug design to rapidly identify candidates with desirable pharmacological features. Its pipeline includes a differentiated HIF-2 alpha inhibitor and other lead candidates intended to be advanced into the clinic. Proceeds from the financing will be used to advance lead drug candidates into the clinic, expand the pipeline, and fund internal drug discovery programs. CBC Group incubated the company and NiKang emphasizes deep insights into disease biology and molecular pathways for target selection. The company has added board members in connection with the financing and is positioning to grow into a leading precision oncology company. NiKang Therapeutics was founded and incubated by CBC Group in late 2017 and is focused on discovering and developing innovative small-molecule medicines to address unmet medical needs. The company has made progress identifying development candidates for several difficult-to-drug targets. NiKang's pipeline centers on oncology programs, and the company plans to advance multiple candidates through preclinical and clinical development. CBC provides strategic direction, operational assistance, and financial support to NiKang. The company completed a significant financing in 2020 that strengthened its balance sheet to support its R&D plans. No operating metrics (revenue/users) are provided in the articles.

• AffaMed Therapeutics

  Participated · Series B · Mar 2021

  AffaMed Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for ophthalmic, neurological and psychiatric disorders. Since its founding in 2019, the company has built a global platform to serve patients in Greater China and worldwide and assembled capabilities in clinical development, regulatory affairs and business development. AffaMed has a pipeline of therapeutic candidates in ophthalmology and neuroscience and plans to advance those programs through clinical development and toward commercialization. Proceeds from the recent financing will be used to advance clinical programs, support business development and partnering activities, and prepare for future commercialization. The company is led by CEO Dr. Dayao Zhao and recently appointed Dr. Ji Li as President and board member to strengthen business development and R&D leadership. AffaMed was founded and initially funded by CBC Group.

No current team members are available.